CRSP (CRSP) Stock Analysis 2026
BriMind AI Score
Proprietary46
Neutral
Price CAGR
15.8%
1Y Return
+9.5%
Analyst Upside
+47.2%
Rev Growth
1041.4%
Score based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.
AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →
Compare CRSP with Peers
VRTX vs CRSPVertex vs CRISPR Therapeutics — Rare Disease Franchise
CRSP vs EDITCRISPR Therapeutics vs Editas Medicine — Gene Editing L
NTLA vs CRSPIntellia Therapeutics vs CRISPR Therapeutics — In-Vivo
BEAM vs CRSPBeam Therapeutics vs CRISPR Therapeutics — Base Editing
SGMO vs CRSPSangamo vs CRISPR Therapeutics — Zinc Finger vs CRISPR
BLUE vs CRSPbluebird bio vs CRISPR Therapeutics — Lentiviral Gene T
Unlock the Full CRSP Analysis
Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.
Data sources: Financial metrics and market data sourced from company SEC filings, earnings releases, and investor relations disclosures. Price data, analyst consensus targets, and fundamental financials provided by financial market data providers. ETF data sourced from official fund prospectuses and index provider publications. AI scores and price targets are proprietary estimates — see our Methodology and Disclaimer for details.